Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Positive COVID-19 vaccine news now provides hope for 2021

By Brian Buntz | December 1, 2020

Coronavirus vaccine

[Image courtesy of Wikipedia]

Throughout much of the world, SARS-CoV-2 infections are seemingly spiraling out of control. Still, there is reason for optimism as a trio of COVID-19 vaccines seems to be on the cusp of winning emergency use authorization in the U.S. 

At least 10 vaccines have entered or completed Phase 3 trials. And by the second half of 2021, COVID-19 infections could begin falling sharply, according to projections from the investment bank UBS. 

Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, recently shared a similar perspective. “I think we will be going in the right direction of some degree of normality as we head into 2021 in the second, third and fourth quarter,” he told the American Medical Association. 

While the prospect of giving two doses of COVID-19 vaccines to roughly two billion people may seem daunting, the investment bank UBS believes strong demand will enable a quarter of the global population to receive vaccines next year. 

Pfizer (NYSE:PFE) and Moderna (NSDQ:MRNA) together could vaccinate nearly 15% of the world’s population. AstraZeneca (LON:AZN) could add an additional 24%. 

But despite the unprecedented speed of COVID-19 vaccine developments, inoculating billions of people across the globe will invariably be a slow process. According to CDC Director Robert Redfield, approximately 40 million doses will be available to Americans by the end of June. 

COVID-19 infections, however, are spreading rapidly in the interim. 

The U.S. could see almost 500,00 deaths by March 1, 2021, according to predictions from the Institute for Health Metrics and Evaluation. The organization predicts that the pandemic’s peak would occur in the first two months of the new year.

By the end of 2021, however, the effects of the pandemic will likely be more muted. UBS projects that roughly 50% or more of the global population could be immune or asymptomatic. In an optimistic scenario, the world could reach herd immunity by that same time frame.  

 


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: covid-19, COVID-19 vaccine, COVID-19 vaccine trial
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at [email protected].

Related Articles Read More >

NIH is reorganizing clinical trial funding by trial type instead of disease
Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE